Learning objectives

After completing this module, participants should be able to:

  • Review the results of cardiovascular outcome trials (CVOTs) with DPP-4 inhibitors
  • Review the results of key CVOTs with GLP-1 receptor agonists including LEADER, SUSTAIN-6, and REWIND
  • Compare results with SGLT2 inhibitor CVOTs
  • Define patients who would benefit from treatment with GLP-1 receptor agonists


Professor Miles Fisher, Honorary Professor, University of Glasgow, Glasgow


1 CPD/CME credit, 1 hour
BJC Learning has assigned 1 hour of CPD/CME credit to this module

You need to login to take this module

You need to be a registered member to view this page. It’s quick, free and offers you a host of other benefits, including the facility to print and download articles and supplements, access our archived issues and receive email updates when new issues and other content are online.

Source: bjcardio.co.uk

Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]